for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Divi's Laboratories Ltd

DIVI.NS

Latest Trade

4,777.30INR

Change

25.10(+0.53%)

Volume

289,153

Today's Range

4,754.10

 - 

4,824.90

52 Week Range

3,153.30

 - 

5,425.10

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
4,752.20
Open
4,776.00
Volume
289,153
3M AVG Volume
11.25
Today's High
4,824.90
Today's Low
4,754.10
52 Week High
5,425.10
52 Week Low
3,153.30
Shares Out (MIL)
265.45
Market Cap (MIL)
1,261,560.00
Forward P/E
52.57
Dividend (Yield %)
0.42

Next Event

Q3 2022 Divi's Laboratories Ltd Earnings Release

Latest Developments

More

SMS Pharma Says "Strongly Condemn" News On Divis Labs Buying Co's Stake

Divi's Labs Currently Experiencing Some Supply Chain Disruptions During India Lockdown Period

India's Divi's Labs Dec-Quarter Profit Falls

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Divi's Laboratories Ltd

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. The Company's geographical segments include India (Sales to customers within India) and other countries (Sales to customers outside India). Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids. It is also involved in developing alternate, non-infringing processes for APIs, for the inventors to manage late life cycle and generic drug manufacturers. The Company develops carotenoids, such as Apocarotenal, Betacarotene, Lycopene, Astaxanthin and Canthaxanthin. It manufactures tert-butoxycarbonyl (BOC), Fluorenylmethyloxycarbonyl (FMOC) and Carboxybenzyl (CBZ) protected amino acids. It manufactures ligands, such as binol and binap. The Company exports its products to European and the American countries. Its manufacturing and research and development facilities are located in the State of Andhra Pradesh and Telangana in India.

Industry

Biotechnology & Drugs

Contact Info

1-72/23(P)/Divis/303

, Divi Towers, Cyber Hills, Gachibowli,

500032

India

+91.40.23786300

http://www.divislabs.com/

Executive Leadership

Ramesh B.V. Nimmagadda

Non-Executive Independent Chairman of the Board

Kiran Satchandra Divi

Chief Executive Officer, Whole-time Director

L. Kishore Babu

Chief Financial Officer

M. Satish Choudhury

Chief Compliance Officer, Company Secretary

Murali Krishna Prasad Divi

Managing Director, Executive Director

Key Stats

2.53 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

49.5K

2020

53.9K

2021

69.7K

2022(E)

82.9K
EPS (INR)

2019

50.960

2020

51.850

2021

74.750

2022(E)

92.810
Price To Earnings (TTM)
59.05
Price To Sales (TTM)
16.96
Price To Book (MRQ)
12.70
Price To Cash Flow (TTM)
52.02
Total Debt To Equity (MRQ)
0.04
LT Debt To Equity (MRQ)
0.03
Return on Investment (TTM)
22.51
Return on Equity (TTM)
20.38

Latest News

Latest News

India's Divi's Labs hits record high on Merck's positive trial data for COVID-19 drug

Shares of India's Divi's Laboratories Ltd, which makes the main ingredient of Merck & Co's experimental antiviral pill, soared 10% on Monday, after the pharmaceutical giant reported positive clinical trial results for the drug.

BRIEF-Divi's Labs Currently Experiencing Some Supply Chain Disruptions During India Lockdown Period

* CURRENTLY EXPERIENCING SOME SUPPLY CHAIN DISRUPTIONS DURING INDIA LOCKDOWN PERIOD

BRIEF-Divi's Laboratories Commences Commercial Production From DCV-SEZ Unit At Chippada Village

* DIVI'S LABORATORIES LTD SAYS COMMENCED COMMERCIAL PRODUCTION EFFECTIVE FROM MARCH 9 FROM DCV-SEZ UNIT AT CHIPPADA VILLAGE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up